World Pharma Newsfeed
Sweeping genetic analysis of rare disease yields common mechanism of hypertension
Analyzing all the genes of dozens of people suffering from a rare form of hypertension, Yale University researchers have...
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world's leading biotechnology companies, and Vera...
'Pulverized' chromosomes linked to cancer?
They are the Robinson Crusoes of the intracellular world - lone chromosomes, whole and hardy, stranded outside the nucle...
Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients
Bristol-Myers Squibb Company (NYSE: BMY) announced a donation of $6.9 million in 2011 to support the HealthWell Foundati...
Continuing uncertainties surround anti-influenza drug
Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug ose...
Novartis receives approval for Lucentis® and launches Galvus® in China
Novartis received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibiz...
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its globa...
Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio
Sanofi (EURONEXT: SAN and NYSE: SNY) is co-investing in Warp Drive Bio, an innovative start-up biotechnology company, al...
Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon
Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a P...
New drug screening identifies chemical agents with potent anti-cancer activity
Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective...

